Trial Profile
A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study to Assess the Effects of Sotatercept (ACE-011) for the Treatment of Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Sotatercept (Primary) ; Antihypertensives
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms SPECTRA
- Sponsors Acceleron Pharma
- 24 Mar 2022 Status changed from active, no longer recruiting to completed.
- 20 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 1 Mar 2022.
- 19 May 2021 Interim results (as of 07 Oct 2020; n=10) presented at the 117th International Conference of the American Thoracic Society.